MedTrace Logo

Transplantation of Autologously Derived Mitochondria Following Ischemia

NCT02851758 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-01-05

No results posted yet for this study

Summary

The investigators propose a robust therapeutic intervention to ameliorate myocardial ischemia/ reperfusion injury and significantly decrease morbidity and mortality in patients requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic mitochondria into the ischemic myocardium.

Conditions

  • Extracorporeal Membrane Oxygenation Complication

Interventions

OTHER

autologous mitochondria transplantation

Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium

Sponsors & Collaborators

Principal Investigators

  • Sitaram M Emani, MD · Boston Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-02
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02851758 on ClinicalTrials.gov